CCL3 and colorectal cancer: Subsequently, after further segmentation testing on TNM staging, it was found that the expression of CCL3 was significantly different among patients with stage 1 and 3 colorectal cancer (P < 0.05); however, there was no correlation with other clinical indicators (P > 0.05).